Fortrea Holdings Inc

FTRENASDAQ · USD
20.15USD0.00 (-1.71%)
5610

Fortrea Holdings Inc (FTRE) Covered Calls

Fortrea Holdings Inc trades in the Biotechnology industry with an IV Rank of 3.97%, low versus the past year. FTRE's highest covered call setup is the $25.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 21.95% out of the money with 30 days to expiration, a 22.44% return until expiration, and a 273.01% theoretical annualized return. Across the setups shown, annualized returns run from 62.41% to 273.01% at strikes between $22.50 and $35.00, with 30 to 184 days to expiration, as of Nov 18, 2026.

Read more

Running FTRE covered calls helps you generate income from Fortrea Holdings Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best FTRE covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If FTRE stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling FTRE covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given FTRE covered call is worth writing.

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures.

2026-12-183025.0021.950.100.90460.0022.44273.01-0.49+0.2260.80
2027-02-199330.0046.340.102.00960.0046.83183.79-0.49+0.2591.90
2027-05-2118435.0070.730.052.701455.0070.98140.79-0.24+0.2602.65
2026-12-183022.509.760.351.35235.0011.46139.47-1.71+0.3501.00
2027-02-199327.5034.150.201.95720.0035.12137.84-0.98+0.2831.75
2027-05-2118432.5058.540.202.801220.0059.51118.05-0.98+0.2802.60
2027-02-199325.0021.951.152.20565.0027.56108.17-5.61+0.38731.05
2027-05-2118430.0046.341.502.951100.0053.66106.44-7.32+0.37441.45
2027-05-2118427.5034.152.002.90900.0043.9087.09-9.76+0.41520.90
2027-05-2118425.0021.951.953.80645.0031.4662.41-9.51+0.47401.85

As of Nov 18, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank3.97% Low
  • Market cap (M$)1,944
  • 52 weeks high-22.97%
  • 52 weeks low135.67%
  • Analyst recommendationBuy
    2.38
  • Target price$24.55
    21.84% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-10-29
  • P/E—
  • Future P/E19.33
  • EPS (ttm)-0.74
  • EPS growth next 5 years44.46%

As of Nov 19, 2026